Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buy stock, stay long and GLTA
Buy stock, stay long and GLTA.
What planet are you from? First clinicals proved concept in practice and science is better today and don't forget totally different application for diabetes clinical soon behind.
A good laugh for the day. Good going, I love it. You made me laugh.
Great question Promise.
BIO, can you name the suitors?
Thanks
Sorry, I corrected my 1-3 week mistake in another post. My comment about lying is just a misunderstanding. I completely agree about a buyout. Dollar value would be too great as you mentioned, many irons in the fire. Licensing agreement for each application, each individual cancer plus diabetes. Also royalties, etc.
I wonder if there's a pharma who would find it economic to buy the whole thing at a fair asset value. Say a compromise on a 5 year figure. Could work if a company's big money makers were going to go out of coverage and the numbers worked. Would have to be a company whose 3, 4, 5, products are going to go generic or PMCB is going to steal their market. I've said this many times, PMCB doesn't have warehouses or trucks. Major pharmas have the distribution systems in place that work. Add to that sales, etc.
Buy stock, stay long GLTA.
Sorry, got it a little wrong, 2 to 3 weeks clinical date will be disclosed. Rest of my comment stands. Buy stock, stay long, GLTA.
Don't be disappointed, between each meaningful advance there are always changes to the plan or approach. Science is that way. Ask any "lab rat." If the reasons for changes in a plan seem reasonable we're ok. if not be disappointed. I think the date change is reasonable. If you think they are lying to you, I guess you should sell. That's only logical.
The interview was really good, clinical "could" start in 1 to 3 weeks. I believe it will take longer. You have the diabetes work to look forward to, too. Please view the video again there's quite a lot there if nothing more than a nice presentation of the companies science. I wonder how long big pharma can resist approaching PMCB. Some of the PMCB science will severely affect a number of big pharma products and their bottom line. That's probably part of the explanation for some of the strange stock action in the past.
Buy PMCB, stay long and GLTA.
News out. Great live interview of KW at Marcum in New York. probably generate a little interest but very cool interview. GLTA.
Is it really the only reason? Really?
As time goes by the clinical big bang is going to happen. After all, we are almost into the 4th Q. Given changes and the difficulty presented before and after each milestone PMCB is doing great. There's only success for those who have patience because the company is doing the right things and success takes time. Could happen in 3rd Q. Soon .06 is going to look very cheap to a lot of people and I don't mean .12. Get long, stay long and GLTA.
Agreed, let's not discount the volatility of the biotech arena especially as the risk is diminished.
Could be and makes sense. There are still may other ways this can go.
Me too Wendy, well said. That's how it's done. IMHO GLTA
PMCB nice and quiet today. That with all change with even a hint of IND or clinical trials or suspected interest by a pharma or partner. Stay long and GLTA.
Just the facts,
Like I said before...........
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
I would say we are just about set....up next IND
Thanks efood.
News on I Hub and yahoo. Head line PMCB to "present" their cancer and diabetes therapies. 9:20 this morning.
As I've mentioned in the past, the accounting system used to judge the value of a stock is still used. Primarily because new technology companies have the ability to recoup and grow revenues much more quickly than did traditional brick and mortar companies. That means, using a 5 year multiple instead of 1 year. Therefore, often, accounting practices often consider revenues going out 5 years. Sooooo, in the case of PMCB we have to look at it's value three ways a deal can be structured. 1. If they sell out completely. 2. If they sell individual treatments. 3. If they license individual treatments. Questions to ask. ref. cancer, how many potentially different cancers are there to be treated with CIAB and what are their individual potential annual revenues. Ask the same thing about diabetes.
I tend to think individual licensing is the best for the share holder and the company but the sale of individual treatments, i.e. pancreases cancer, breast cancer, etc will bring immediate higher valuations and I'm not adverse to that. Without using the 5 year multiple, try this. One treatment at a time.
Take annual revenue multiply it by a P&E of say maybe 12 or more realistically something closer to 20. Divide by appropriate number of shares. That's your share value. Now if you want to use the 5 years earning numbers and a P&E of 20 you get some significant numbers. Using 1 year the numbers are significant but no one wants to give away the earnings of 4 years.
Finally, all of this is moot because the real deal is made over the table face to face. Remember the management of this company is not new to this rodeo and know what's going on.
ps. let's not forget mergers, doubtful but still there. Let's not forget stem cell potential. CIAB addresses all the problems. immune response and traveling cells.
Morning everyone, just a waiting game. The fun of waiting is knowing great things can happen at any minute. Stay long and GLTA.
Nice post and good info, Thanks Bio.
These forums are called dog and pony shows for a reason. Basically to strut their stuff, first in the biotech world to get some standing and second hopefully to interest a pharma or 2 or 3. It's a desirable thing to be there and another part of the puzzle to a successful outcome for PMCB. Good job to KW and all the PMCB team. Great advertising and exposure and also nice for a shareholder to hear. Stay long and GLTA
Nothing is written in stone. It's like trying to get worms to move in sync. Difficulties pop up. It's just development.
Actually, I forgot about that. LOL It's too good, thanks Pete. Stay long and GLTA.
Anyone wonder why sellers picked today of all days to demonstrate? Good news or a great performance frightens them to death and in their two demensional thinking, they believe share price going down on selling pressure will discourage buyers and longs from buying or owning the stock. They don't understand the compelling facts of PMCB create buyers especially at their artificially created lower prices. I have a ton and never sold a share even when it went up and under .07 the buyers are there. LOL Stay long and GLTA.
WEAK, the weakest.
If you want to watch KW's presentation as featured speaker, tomorrow at 9:30 am go to link in news release.
Sure looks real to me.
What does that mean?
So much has been improved since the early successful trials to include manufacturing capabilities through things like nano tech and genetic engineering, and on and on. We are close , very close.
This is the future.
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
I would say we are just about set....up next IND
This is the future.
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
I would say we are just about set....up next IND
Yes, one of many positive components.
This is what's important, the whole and true story.
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
Rico is coming
This is whats important, the whole and true story
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
Thanks efood
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
I would say we are just about set....up next IND
And finally, the facts
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
Add to that 7 or 8 cancer treatments multiply by 12 to 20 your choice then divide by 770 million shares. What's that number?
Just the facts
Fda ODD....check
Ema ODD. .....check
cGMP.....check
CRO (TD2)....check
Experts on board....check
Clinical trial locations....check
Patents secured.....check
Thanks efood.